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Abstract
Background: Neuronal synaptic junction protein δ-catenin (CTNND2) is often overexpressed in prostatic
adenocarcinomas but the mechanisms of its activation are unknown. To address this question, we studied the
hypothesis that Hes1, human homolog of Drosophila Hairy and enhancer of split (Hes) 1, is a transcriptional
repressor of δ-catenin expression and plays an important role in molecular carcinogenesis.
Results: We identified that, using a δ-catenin promoter reporter assay, Hes1, but not its inactive mutant,
significantly repressed the upregulation of δ-catenin-luciferase activities induced by E2F1. Hes1 binds directly to the
E-boxes on δ-catenin promoter and can reduce the expression of δ-catenin in prostate cancer cells. In prostate
cancer CWR22-Rv1 and PC3 cell lines, which showed distinct δ-catenin overexpression, E2F1 and Hes1 expression
pattern was altered. The suppression of Hes1 expression, either by g-secretase inhibitors or by siRNA against Hes1,
increased δ-catenin expression. g-Secretase inhibition delayed S/G2-phase transition during cell cycle progression
and induced cell shape changes to extend cellular processes in prostate cancer cells. In neuroendocrine prostate
cancer mouse model derived allograft NE-10 tumors, δ-catenin showed an increased expression while Hes1
expression was diminished. Furthermore, E2F1 transcription was very high in subgroup of NE-10 tumors in which
Hes1 still displayed residual expression, while its expression was only moderately increased in NE-10 tumors where
Hes1 expression was completely suppressed.
Conclusion: These studies support coordinated regulation of δ-catenin expression by both the activating
transcription factor E2F1 and repressive transcription factor Hes1 in prostate cancer progression.
Background
Deregulation of gene expression is one of the most pro-
minent features of cancer. Upregulated or downregu-
lated genes interfere with signaling pathways leading to
altered cell functions. Thus, the elucidation of different
mechanisms responsible for changes in gene expression
is essential for the understanding of tumorigenesis.
δ-Catenin (CTNND2) or NPRAP (neural plakophilin-
related arm-repeat protein) was first identified with its
primary expression in neural and neuroendocrine tissues
[1]. Many studies showed that δ-catenin expression is
tightly controlled, and the alteration of its expression
level is associated with a number of human diseases.
The hemizygous deletion of δ-catenin gene is associated
with the severe mental retardation phenotype of Cri-du-
Chat syndrome [2]. On the other hand, increased
δ-catenin expression modifies adhesion molecules,
reshapes cellular morphology, and promotes cell migra-
tion [3,4]. Most strikingly, δ-catenin was found to be
overexpressed in several cancers of peripheral tissues,
including prostate, esophagus, and breast tumors [5],
and upregulated in the majority of prostatic adenocarci-
nomas [6]. Overexpressed δ-catenin can be detected in
urine and is accumulated significantly in prostate cancer
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any medium, provided the original work is properly cited.patients [7]. Increased expression of δ-catenin disrupts
cell-cell junctions [3,6] and promotes human prostate
cancer cell growth and tumor progression, altering cell
cycle and survival gene profiles [8].
Increased expression of δ-catenin in carcinogenesis is
modulated by multiple mechanisms, including gene
amplification, transcriptional activation, and mutation in
its non-coding region [9]. It was reported that E2F1
positively regulates the expression of δ-catenin in
human prostate cancer cells [10], and the expression of
both genes is altered in prostate cancer [6,11]. On the
other hand, Hes1, human homolog of Drosophila Hairy
and enhancer of split 1, and a basic helix-loop-helix
(bHLH) transcriptional repressor, shows potential bind-
ing sites on human δ-catenin promoter region near that
of E2F1 [10]. Hes1 is a target gene of Notch1 activation,
which is believed to be critical for the development of
prostate cancer [12,13]. In transgenic mouse models of
prostate cancer, NE-10 prostate tumor from subcuta-
neous transplantation of 12T-10 tumor and CR2-TAg
prostate, Notch-Hes1 signaling is down-regulated and
may be responsible for the promotion of the neuroendo-
crine differentiation of prostate cancer cells [14,15].
δ-Catenin is upregulated in human prostate cancer [6],
and Hes1 expression is altered in tumorigenesis [16,17].
However, the ability of Hes1 to inhibit the expression of
δ-catenin in prostate cancer cells and the cooperation
between Hes1 and other transcription factors for modu-
lating δ-catenin expression in prostate development and
tumorigenesis are still unclear. In this study, we demon-
strated that Hes1 is a transcriptional repressor for δ-
catenin and regulates δ-catenin expression in human
prostate cancer cells and mouse models of prostate
tumors by coordinating with transcription activator
E2F1.
Results
Hes1 inhibits the upregulation of δ-catenin-luciferase
activities induced by E2F1 in prostate cancer cells
Human δ-catenin promoter region contains multiple
potential binding sites for positive or negative regulators
revealed by Genomatix program http://www.genomatix.
de/[10]. Among them, E2F1 has been identified as a
positive regulator of δ-catenin expression in prostate
cancer cells. On the other hand, Hes1 was predicted to
have several binding sites near the binding sites of E2F1
on δ-catenin promoter (Figure 1A). BK1 and BK5 were
two δ-catenin-luciferase reporter vectors, containing
2664 bp and 744 bp of δ-catenin promoter, respectively.
When co-transfected with E2F1 expression vector, δ-
catenin-luciferase activities were dramatically increased
in prostate cancer cell lines [10]. To test the hypothesis
that Hes1 is a negative regulator of δ-catenin expression,
we co-transfected Hes1 expression vectors (pcDNA-flag-
WT-Hes1 or pcDNA-flag-DN-Hes1)a n dE2F1,t o g e t h e r
with δ-catenin-luciferase reporter vectors BK1 or BK5,
into CWR22-Rv1 or PC3 human prostate carcinoma cell
lines. As shown in Figure 1B, E2F1 induced dramatic
increases in δ-catenin-luciferase activities in both cell
lines with either BK1 or BK5 co-transfection. After co-
transfection with WT-Hes1 expression vector, E2F1-
induced δ-catenin-luciferase activities were completely
blocked in both cell lines (Figure 1B). We then applied
a dominant negative mutant Hes1 (DN-Hes1), where
amino acids E43, K44, and R47 in the basic region were
each mutated to A. Literature indicated that DN-Hes1
cannot bind to DNA but can still dimerize with the
endogenous WT-Hes1 to form a non-DNA-binding het-
erodimer complex [18]. DN-Hes1 led to a moderate
reduction in E2F1-induced δ-catenin-luciferase expres-
sion in PC3 (Figure 1B) that did not reach statistical sig-
nificance. No change was found in CWR22-Rv1 cells
(Figure 1B). The negative effects of Hes1 on E2F1-
induced δ-catenin-luciferase activities were dose-depen-
dent (Figure 1C). Furthermore, when Hes1 expression
was kept constant, increasing E2F1 expression also
showed dose-dependent changes in δ-catenin-luciferase
activities (Figure 1D). These results demonstrated that
Hes1 can functionally interact with E2F1 in controlling
δ-catenin expression in prostate cancer cells.
Hes1 interacts with δ-catenin promoter
To explore whether Hes1 suppresses δ-catenin expres-
sion by directly binding to δ-catenin promoter, we
performed electrophoretic mobility shift assay (EMSA).
δ-Catenin promoter contains several E-boxes and
N-boxes (Figure 1A). We applied biotin to label and
prepare a 60 bp dsDNA oligonucleotide probe (marked
as ** in Figure 1A) spanning one E-box. Nuclear extracts
were prepared from PC3 or CWR22-Rv1 cells that were
transiently transfected with Hes1 for 24 hours. EMSA
demonstrated a clearly shifted protein-DNA complex
after incubating the labeled probes with nuclear extracts
from cells overexpressing WT-Hes1 (Figure 2A, lane 2,
and arrow). This shift was also observed when the
E-box was mutated in the unlabeled probes and
incubated with nuclear extracts of cells overexpressing
W T - H e s 1( F i g u r e2 A ,l a n e3 ,a r r o w ) .C o m p e t i t i o n
experiments showed that the unlabeled δ-catenin
promoter sequences applied at low dose reduced Hes1
protein-δ-catenin promoter complexes (Figure 2A, lane
4, arrow), whereas that of high dose completely inhib-
ited the Hes1 protein-δ-catenin promoter complexes
(Figure 2A, lane 5, arrow). To determine whether Hes1
was responsible for the formation of the shifted protein-
DNA complexes, we added anti-Hes1 antibody into the
nuclear extracts followed by the gel-shift immunoassays.
After incubating Hes1-overexpressed nuclear extracts
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Page 2 of 16Figure 1 Hes1 inhibits δ-catenin transcription in prostate cancer cells. (A) A schematic graph showing predicted binding regions of Hes1,
E2F1, and p53 on δ-catenin promoter. Numbers on top indicate the sequence location in base pairs from the transcription start site. (B) Hes1 is
a negative regulator of δ-catenin transcription. E2F1, WT-Hes1 and DN-Hes1 expression vectors together with two human δ-catenin-luciferase
reporter vectors (BK1 and BK5) and a control vector (pGL3-Basic), were co-transfected into PC3 and CWR22-Rv1 cells (0.2 μg/well for each vector
in 12-well plates) as indicated. Hes1 blocked δ-catenin-luciferase activity completely, which was induced by E2F1. DN-Hes1 did not block E2F1
induced δ-catenin-luciferase activity, regardless of cell types and reporter vectors used. (C and D) Hes1 inhibited δ-catenin-luciferase activity (BK5
reporter vector) in a dose-dependent manner. PC3 cells were co-transfected with pcDNA-flag-WT-Hes1 and E2F1 vectors. (C) E2F1 plasmid was
used at 0.2 μg/well and pcDNA-flag-WT-Hes1 plasmid was used for co-transfection at 0.02 μg, 0.04 μg, 0.1 μg and 0.2 μg per well separately in
12-well plates. (D) pcDNA-flag-WT-Hes1 plasmid was used at 0.05 μg/well and E2F1 plasmid was used for co-transfection at 0.3 μg, 0.2 μg, 0.1 μg
and 0.05 μg per well separately in 12-well plates. The data was representative of three independent experiments.
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Page 3 of 16Figure 2 Hes1 interacts with δ-catenin promoter. (A) EMSA to show direct binding of Hes1 to δ-catenin promoter. Lane 1, control (labeled δ-
catenin promoter probe spanning the HLH motif, marked as ** in the Figure 1A); lane 2, labeled probe with WT-Hes1 overexpressed nuclear
extracts, forming DNA-protein complexes (indicated by arrow); lane 3, unlabeled probe with E-box mutated, showing DNA-protein complexes;
lane 4, unlabeled competitor + nuclear extracts + labeled probe, low dose unlabeled probe reduced the binding of protein-DNA complexes;
lane 5, unlabeled competitor + nuclear extracts + labeled probe, high dose unlabeled probe inhibited the binding of protein-DNA complexes;
lane 6-7, gel shift immune-assays were performed with the same labeled probe using an anti-Hes1 antibody. Incubating Hes1-overexpressed
nuclear extracts with anti-Hes1 antibody before the addition of probe DNA inhibited protein-DNA complexes (lane 6). Incubating Hes1-
overexpressed nuclear extracts with anti-Hes1 antibody after the addition of probe DNA disrupted the slowest moving protein-DNA complexes
(lane 7, arrow). However, under this experimental condition, supershifts did not occur but the partially disrupted protein-DNA complex resulting
fast moving band accumulation can be detected (lane 7, double arrows). (B) Anti-Hes1 chromosome immunoprecipitation (ChIP) of the δ-catenin
promoter. Real-time qRT-PCR showed the signal relative to input chromatin. Compared with the negative control experiment using IgG, anti-
Hes1 greatly recruited the δ-catenin promoter DNA. Anti-Histone H3 ChIP was performed as a positive control. *: p < 0.05. (C) Hes1 binding to E-
boxes on δ-catenin promoter is important to negatively regulate E2F1 induced δ-catenin-luciferase reporter activity. Note: E2F1 expression elicited
a strong δ-catenin-luciferase reporter activity in PC3 cells, whatever BK5 sequence was mutated (*p > 0.05). But when WT-Hes1 co-transfection
with E2F1, it significantly suppressed E2F1 induced δ-catenin-luciferase reporter activity when wild type δ-catenin promoter sequence BK5 was
employed compared to BK5 sequence mutated vector (*p< 0.05).
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Page 4 of 16with anti-Hes1 antibody before the addition of DNA
probe, protein-DNA complexes related to Hes1-δ-cate-
nin promoter disappeared (Figure 2A, lane 6, arrow). In
other experiments, incubation of nuclear extracts with
normal IgG or antibodies against non-relevant proteins
did not reduce shifted bands (data not shown). When
anti-Hes1 was added after the probe was incubated with
the nuclear extracts, the slowest moving protein-DNA
complexes were disrupted. However, under this experi-
mental condition, supershifts did not occur but the par-
tially disrupted protein-DNA complex can be detected
(Figure 2A, lane 7, double arrows).
We have also performed the ChIP assay to further
examine the interaction of endogenous Hes1 protein
with δ-catenin promoter. The signal relative to input
chromatin revealed by real-time PCR showed that anti-
Hes1 recruited the δ-catenin promoter DNA to the
similar levels to the positive control using anti-Histone
3 (Figure 2B). These combined results including EMSA
and CHIP demonstrated that endogenous as well as
ectopically transfected Hes1 protein is capable of direct
binding to the δ-catenin promoter.
Additionally, to determine whether Hes1 binding
domain on δ-catenin promoter is functional, we exam-
ined the ability of Hes1 protein to inhibit δ-catenin-luci-
ferase reporter activity when selective, putative Hes1
binding E-boxes on δ-catenin promoter were mutated
(Figure 2C). As shown in Figure 2C, E2F1 expression
elicited a strong δ-catenin-luciferase reporter activity in
PC3 cells, whether the BK5 sequence was mutated or
not. WT-Hes1 co-transfection with E2F1 significantly
suppressed E2F1 induced δ-catenin-luciferase reporter
activity when wild type δ-catenin promoter sequence
BK5 was employed. However, the ability of WT-Hes1 to
suppress E2F-1 induced δ-catenin-luciferase reporter
activity was reduced when BK5 sequence was mutated
(p < 0.05) (Figure 2C). Therefore, Hes1 was able to bind
to δ-catenin promoter and repress its activity through E-
boxes, although other potential Hes1 binding sites may
play additional suppressive roles on δ-catenin promoter.
Prostate cancer cell lines display altered expression of δ-
catenin and its potential transcription regulators
Our previous studies demonstrated δ-catenin upregula-
tion in prostate cancer by both RT-PCR and immuno-
histochemistry [6]. Overexpression of δ-catenin in
prostatic adenocarcinomas could be due to increased
activities of its positive transcriptional regulators and/or
decreased activities of its negative transcriptional regula-
tors. To further exploit the potential transcriptional reg-
ulators of δ-catenin in prostate cancer cells, we applied
RT-PCR to compare the expression patterns of potential
transcription factors in CWR22-Rv1 and PC3, two
prostate cancer cell lines that show distinctly higher δ-
catenin expression compared to the non-cancer prostate
epithelial cell line PZ-HPV-7 (Figure 3A, δ-catenin).
Coincident with δ-catenin expression, E2F1 expression
correlated very well with CWR22-Rv1 and PC3 while it
was barely detected in PZ-HPV-7 (Figure 3A, E2F1).
Hes1 expression was clearly detected in all of these cell
lines. Hey1,a n o t h e rHes related family of bHLH type
transcriptional repressors, had a similar transcript distri-
bution pattern in these cells compared with that of Hes1
(Figure 3A, Hes1 and Hey1). Real-time qRT-PCR con-
firmed the RT-PCR results (Figure 3B). Pax6, another
known positive transcription factor for δ-catenin [10],
showed similar changes to E2F1 in CWR22-Rv1 cells
and PC3 cells compared with PZ-HPV-7 cells (Figure 3,
Pax6). The expression of p53 and androgen receptor
(AR) did not show clear correlation with δ-catenin
expression. These data indicate that E2F1 and Hes1 may
influence δ-catenin transcript level in prostate cancer
PC3 or CWR22-Rv1 cells.
Overexpression of Hes1 can reduce the expression of δ-
catenin in prostate cancer cells
We then examined whether ectopic overexpression of
Hes1 can act as a negative regulator of δ-catenin
expression in prostate cancer cells. When pcDNA-flag-
WT-Hes1 was transfected into CWR22-Rv1 cells, both
δ-catenin mRNA and protein levels were reduced dra-
matically compared to control and DN-Hes1 (Figure
4A and 4B). The same trends can be observed in PC3
cells, however the reduction of δ-catenin mRNA
and protein was more moderate (only 10%, p <0 . 0 5 )
(Figure 4C and 4D).
We then applied immunofluorescence light microscopy
to investigate the expression and distribution of Hes1 and
δ-catenin in CWR22-Rv1 and PC3 cells. Anti-flag-M5
antibody for flag-tagged Hes1 did not stain control,
untransfected cells as expected (Figure 5A) but labeled
strongly the nuclei when Hes1 was overexpressed in
CWR22-Rv1 cells (Figure 5B and N, arrows). CWR22-Rv1
cells were clustered so we applied marking lines to better
reveal the cell-cell boundary (Figure 5K and 5L). Anti-δ-
catenin stained cytoplasm and cell-cell contacts in
untransfected cells (Figure 5D), but the transfected cells
showed a decreased intensity of anti-δ-catenin immunor-
eactivity (Figure 5E and N, arrows) when compared with
the nearby untransfected cells (Figure 5E, arrowheads).
The same results were obtained in PC3 cells that the over-
expression of Hes1 reduced the anti-δ-catenin immunor-
eactivity (Figure 6B, E and N, arrows and arrowheads).
However, when dominant negative Hes1 (pcDNA-flag-
DN-Hes1) was transfected in either CWR22-Rv1 cells or
PC3 cells, its inhibitory effects on the expression of δ-
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Page 5 of 16Figure 3 RT-PCR and real-time qRT-PCR analyses of mRNA expression of δ-catenin and its potential transcriptional regulators. (A) RT-PCR.
Total RNAs were prepared from human prostate cancer cell lines (PC3 and CWR22-Rv1) and a non-cancer prostate cell line (PZ-HPV-7). RT-PCR
analyses were performed to determine the mRNA expression of Hes1, Hey1, E2F1, Pax6, p53, AR,a n dδ-catenin genes. GAPDH was used as control.
Numbers beneath each lane are the semi-quantification of RT-PCR data normalizing to GAPDH.( p < 0.05) (B) Real-time qRT-PCR analyses of relative
mRNA levels of E2F1, Hes1,a n dδ-catenin in comparison to GAPDH. While the trends were clear that the transcript levels of E2F1 and Hes1 were higher
in PC3 cells than that in CWR22-Rv1 cells, they were not statistically significant. Three independent experiments were performed.
Figure 4 Overexpression of Hes1 suppressed the δ-catenin expression. (A) Western blots showing the expression of δ-catenin, Hes1, and
actin in total lysates of CWR22-Rv1 cells transfected with WT-Hes1, DN-Hes1 or pcDNA3 (vector as control), respectively. (B) RT-PCR analysis of the
expression of δ-catenin, Hes1, and GAPDH genes in CWR22-Rv1 cells transfected with WT-Hes1, DN-Hes1 or pcDNA3, respectively. (C) Western blots
showing the expression of δ-catenin, Hes1, and actin in total lysates of PC3 cells transfected with WT-Hes1, DN-Hes1 or pcDNA3, respectively. (D)
RT-PCR analysis of δ-catenin, Hes1, and GAPDH gene expression in PC3 cells transfected with WT-Hes1, DN-Hes1 or pcDNA3, respectively. Note:
Actin or GAPDH as either Western blot or RT-PCR control. The numbers beneath each gel lane reflects the relative intensity compared to vector
control and normalized against actin or GAPDH (p < 0.05). Both the Western blot and RT-PCR experiments were repeated at least three times.
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Page 6 of 16catenin were very weak, comparable to that of control,
untransfected cells (Figure 5 and 6, C, F and O, compare
arrows and arrowheads). Combined with the RT-PCR and
Western blot data (Figure 4), these studies suggest that
overexpression of wild type Hes1 can reduce the expres-
sion of δ-catenin in prostate cancer cells.
Suppression of endogenous Hes1 expression increases δ-
catenin expression in prostate cancer cells
It was reported that g-secretase inhibitor DAPT reduced
Hes1 level in two prostate tumor cell lines, PC3 and
LNCaP, in a dose-dependent manner [19]. After being
treated with 20 μM DAPT for 48 h, Hes1 expression
Figure 5 Immunofluorescence light microscopy of CWR22-Rv1 cells transfected with WT-Hes1, DN-Hes1 or pcDNA3, respectively.R e d
shows Hes1 protein stained by anti-flag-M5 antibody. Green shows δ-catenin stained by R1152 antibody. Blue shows nuclei stained with
Hoechst 33258. To better reveal the cell-cell boundary in otherwise clustered CWR22-Rv1 cells, purple lines were drawn to indicate the cells
transfected while the green lines marked the cells untransfected in K and L. Arrows (B, E, H, K and N): cells transfected with WT-Hes1; Arrows (C,
F, I, L and O): DN-Hes1. Arrowheads: cells transfected with pcDNA3. Bar: 10 μm.
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Page 7 of 16showed a decreasing trend at both the mRNA and pro-
tein level in PC3 cells (Figure 7A and 7B). Correspond-
ingly, δ-catenin mRNA and protein levels in PC3 cells
increased markedly (Figure 7A and 7B). The changes of
E2F1 mRNA expression were less clear in PC3 cells
(Figure 7B). These results were consistent with the
notion that the relief of inhibitory function of Hes1 by
DAPT may increase the δ-catenin expression in PC3
cells.
In CWR22-Rv1 cells, treatment with 20 μM DAPT for
48 h also reduced Hes1 expression but with little
changes in E2F1 expression; the expression of δ-catenin
in transcript and protein levels only showed a slight
increase (Figure 7C and 7D, p <0 . 0 5 ) .T od i r e c t l yt e s t
the hypothesis that a reduction of Hes1 can lead to
increases in δ-catenin expression, we applied siRNA
against Hes1 to knock down endogenous Hes1 expres-
sion in PC3 cells (Figure 7E). Real-time PCR clearly
Figure 6 Immunofluorescence light microscopy of PC3 cells transfected with WT-Hes1, DN-Hes1 or pcDNA3, respectively. Red shows
Hes1 protein stained by anti-flag-M5 antibody. Green shows δ-catenin stained by R1152 antibody. Blue shows nuclei stained with Hoechst
33258. Arrows (B, E, H, K and N): cells transfected with WT-Hes1; Arrows (C, F, I, L and O): DN-Hes1. Arrowheads: cells transfected with pcDNA3.
Bar: 10 μm.
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Page 8 of 16Figure 7 Reduction of Hes1 corresponds to increased δ-catenin expression. (A-D). Inhibition of g-secretase decreases Hes1 expression while
increasing δ-catenin expression. PC3 (A and B) and CWR22-Rv1 (C and D) cells were treated with (DAPT) or without (Control) the g-secretase
inhibitor DAPT at 20 μM for 48 hours. DAPT reduced Hes1 expression and increased δ-catenin expression. (A) Western blot analyses showing
Hes1 and δ-catenin expression in PC3 cells with GAPDH as a loading control. (B) RT-PCR analyses for Hes1, E2F1 and δ-catenin in PC3 cells with
GAPDH as PCR control. (C) Western blot analyses showing Hes1 and δ-catenin expression in CWR22-Rv1 cells with GAPDH as a loading control.
(D) RT-PCR analyses for Hes1, E2F1 and δ-catenin in CWR22-Rv1 cells with GAPDH as PCR control. (E-F). siRNA against Hes1 suppressed Hes1
expression while increasing δ-catenin expression in PC3 cells. (E). siRNA against Hes1 nearly depleted Hes1 expression level compared to
scrambled siRNA as a transfection control. (F). siRNA against Hes1 increased δ-catenin expression level by 6-fold compared to scrambled siRNA as
a transfection control. KD: Knockdown. Two independent experiments were performed.
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Page 9 of 16showed that depletion of Hes1 mRNA increased δ-cate-
nin transcript level by over 6-fold (Figure 7F).
δ-Catenin shows a coordinated expression with E2F1 and
Hes1 in NE-10 mouse model of prostate cancer
NE-10 is a tumor derivative allograft from the neuroen-
docrine prostate cancer mouse model 12T-10 [20]. Pre-
vious reports showed that compared to the normal
mouse prostate, Hes1 expression was suppressed in NE-
10 tumors [14]. This was confirmed in our studies (Fig-
ure 8A, left panel). Both RT-PCR and immunohisto-
chemistry also showed that δ-catenin immunoreactivity
was increased in NE-10 tumors when compared to that
of normal prostate (Figure 8A, left and right panels). To
d e t e r m i n ew h e t h e rac o o r d i n a t e dr e g u l a t i o no fE 2 F 1
with Hes1 on δ-catenin expression occurs in vivo,w e
have sought to compare the changes of δ-catenin
expression along with Hes1 and E2F1 expression in NE-
10 tumors and normal prostates. By using RT-PCR and
real-time qRT-PCR, we found that Hes1 expression in
NE-10 tumors was diminished whereas δ-catenin
expression was correspondingly increased (Figure 8A
and 8B). The majority of NE-10 tumors also showed an
increased expression of E2F1 (Figure 8A, left panel).
However, when E2F1 levels from all NE-10 tumors were
examined collectively by real-time qRT-PCR, they were
quite variable; it did not show statistically significant dif-
ferences between the NE-10 tumors and normal prostate
specimens (Figure 8B, n = 12). A closer examination led
us to find that, among the 11 NE-10 tumors in which
Hes1 expression was already very low, E2F1 transcrip-
tion was relatively high when Hes1 level was corre-
spondingly high (Figure 8C). When the E2F1
transcription was relatively low, Hes1 expression was
extremely low (Figure 8C). These results were consistent
with the notion that the changes of δ-catenin expression
in NE-10 tumors could be the result of coordinated reg-
ulation of Hes1 and E2F1 expression.
g-Secretase inhibitors alter cell cycle progression and
induce cellular processes in prostate cancer cells in
culture
Because g-secretase inhibitor DAPT reduced Hes1 level
in prostate cancer cell lines [19] (see also Figure 7), we
Figure 8 Expression of transcriptional regulators of δ-catenin in NE-10 mice bearing prostate tumors. (A) Left panel: RT-PCR of δ-catenin,
Hes1 and E2F1 gene expressions in one representative set of normal prostate (10 week old CD1 mouse) and NE-10 tumor tissues [14]; Right
panel: Immunohistochemistry showing increased δ-catenin expression in NE-10 mouse tumor specimen as compared to a normal mouse
prostate. a. Normal mouse prostate tissue. b. NE-10 tumor tissue. Original magnification: x400. (B) Comparison of real-time qRT-PCR of δ-catenin,
Hes1, and E2F1 gene expression between normal prostate and NE-10 tumors (GADPH as control). While δ-catenin transcript level was consistently
increased, Hes1 expression was diminished. However, E2F1 transcript level varied greatly. (C) Comparison of real-time qRT-PCR of Hes1 and E2F1
gene expression among NE-10 tumors. Among the 11 NE-10 tumors, E2F1 transcription was relatively high when Hes1 level was correspondingly
high. When the E2F1 transcription was relatively low, Hes1 expression was extremely low. These experiments were repeated twice, and the
results were similar.
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Page 10 of 16sought to explore whether the g-secretase inhibition-
mediated increases in δ-catenin expression is accompa-
nied by phenotypic changes with implications of neu-
roendocrine alterations. We examined the cell cycle
profiles and the morphology of PC3 cells. After treat-
ment with DAPT, there were no significant changes in
G1 or SubG1 populations when compared to control
PC3 cells (Figure 9A). However, there were significant
increases (p < 0.05) in cell number in the S phase with
corresponding decreases in the G2/M populations, indi-
cating a delay in S/G2 transition (Figure 9A). Similar
results were obtained in additional experiments using
another g-secretase inhibitor WPE-III-31C, although its
effects were more moderate (Figure 9A).
PC3 cells in rapid growth phase showed typical
epithelial cell morphology (Figure 9B). However, PC3
cells treated with DAPT or WPE-III-31C for 48 hours
altered cell morphology. They displayed increased
number of cells with elongated shape or with extended
cellular protrusions (Figure 9C, DAPT; Figure 9D,
WPE-III-31C; see arrows). These results are consistent
with previously reporte df u n c t i o n so fH e s 1a n dδ-cate-
nin and support a role of Hes1 suppression and δ-cate-
n i ne x p r e s s i o ni nn e u r o e n d o crine tumor progression
[21-23].
Discussion
δ-Catenin expression is upregulated in most human pro-
static adenocarcinomas [6] and other epithelial cancers
[5]. Recently, Pax6 and E2F1 were identified as positive
transcriptional regulators for δ-catenin in the central
n e r v o u ss y s t e m[ 2 4 ]a n di np r ostate cancer cells [10].
However, whether there are pivotal negative transcrip-
tional regulators for δ-catenin and how they may coordi-
nate with positive regulators to control δ-catenin
expression are unknown.
Transcriptional factor binding consensus analysis
using Genomatix program http://www.genomatix.de/
revealed that δ-catenin promoter region contains poten-
tial binding sites of negative transcriptional regulators,
RBP-Jkappa, Hes1, and p53 [10]. We have found that
PC3 and CWR22-Rv1 are two prostate tumor cell lines
Figure 9 Inhibition of g-secretase altered PC3 cell cycle progression and increased cellular processes. (A) Percentage of cell populations
in each cell cycle stages (G1, S, G2/M and SubG1) of PC3 cells treated with or without g-secretase inhibitors (DAPT or WPE-III-31C). * p < 0.05. (B-
D) Morphology of PC3 cells treated for 48 hours with DMSO (B, control), DAPT (C) or WPE-III-31C (D). Note: Inhibition of g-secretase showed
increased number of cells with elongated shape or with extended cellular protrusions (Arrows) in PC3 cells (C and D). 31C: WPE-III-31C. Three
independent experiments were performed. Bar: 50 μm.
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and Hes1.
While a single transcription activator or repressor less
likely controls δ-catenin expression in prostate cancer
cells, our current study supports the notion that Hes1
could negatively regulate the expression of δ-catenin in
prostate cancer cells. Similar to the positive effects of
E2F1 [10], Hes1 acts negatively on δ-catenin expression
in a dose-dependent manner.
Hes1 expression is downregulated in non-metastatic
cancer cell LNCaP compared with that in metastatic
cancer cell C4-2B and may act as a tumor suppressor
for primary prostate tumorigenesis [19,25]. In breast
and pancreatic endocrine tumors, Hes1 was also down-
regulated [16,17]. However, in some tumors, Hes1 is
upregulated during tumorigenesis, such as osteosarco-
mas [26,27]. As tumorigenesis is further underway, gene
expression in cancer cells is deregulated and seems to
be very complex and multi-faceted in nature. Hes1 may
thus act as a tumor suppressor in one context and as an
oncogene in another depending on the tumor types and
the stages of cancer progression.
Notch-Hes1 axis in signaling is intricately modulated
to control proliferation, differentiation, and apoptosis
[28]. Hes1 is a target of Notch1 signaling, which is aber-
rantly activated in a variety of human cancers, including
prostate, lung, colorectal, osteogenic, and breast carcino-
mas [12,13,26,29,30]. Hes1 may also contribute to osteo-
blast growth and differentiation by controlling
transcription directly through interactions with tran-
scriptional regulators [30]. The relationship between the
aberrant expression of Hes1, E2F1, and δ-catenin in
tumorigenesis is quite complex in vivo as well. In NE-10
neuroendocrine tumors [20] where δ-catenin expression
was increased, Hes1 expression was diminished and
E2F1 expression was increased. However, the extent of
Hes1 reduction and E2F1 upregulation appeared to be
tightly controlled in NE-10 tumors to avoid a complete
shutdown of Hes1 expression with an overwhelming
upregulation of E2F1 at the same time. One conse-
quence of this coordination is for tumor cells to watch
closely the expression level of δ-catenin during tumor
progression. Therefore, it is possible that δ-catenin
expression in NE-10 tumor is regulated both by its posi-
tive and negative transcriptional regulators.
These findings may have important functional impli-
cations for gene deregulation in tumor progression. It is
well documented that Myc oncoprotein can activate
E2F transcription factor, which can initiate both cell
proliferation and apoptosis [31]. Earlier studies found
that E2F1 transgenic mice showed increases in sponta-
n e o u st u m o rf o r m a t i o ni nt h es k i n ,b u tt h e ya l s od i s -
played an inhibition of tumor promotion by O-
tetradecanoyl-phorbol-13-acetate (TPA) [32]. A closer
examination of E2F1 expression using tissue microarray
found that E2F1 was low in benign and localized pros-
tate cancer, modestly elevated in metastatic lymph
nodes from hormone-naive patients, and significantly
elevated in metastatic tissues from hormone-resistant
prostate cancer patients [33]. These studies suggest that
in the early stages of prostate cancer development, E2F1
may be kept low to allow its oncogenic effects to be
best accomplished with the cooperation of other onco-
genic proteins, such as Myc, to outweigh its potential
apoptotic effects. Quite interestingly, δ-catenin expres-
sion increased correspondingly from Gleason 4 to 6 and
peaked at Gleason 8 prostatic adenocarcinomas, but
reduced somewhat at Gleason 10 tumors, although its
overall level was still higher than that of non-cancer
prostatic tissues [6]. It is possible that in individual
human prostate cancer cases, simultaneously higher δ-
catenin and E2F1 expression level during early cancer
development is not beneficial for tumor growth. On the
other hand, an unusually high δ-catenin as well as E2F1
expression [33] could indicate the aggressiveness of
tumor progression as they could signal that the tumors
have already passed the very early stage of the onco-
genic buildup.
Conclusion
Our study shows that human homolog of Drosophila
Hes1 negatively regulates δ-catenin (CTNND2)e x p r e s -
sion, alters cell cycle progression, and influences neu-
roendocrine-like cell morphology. These studies support
coordinated regulation of δ-catenin expression by both
the activating transcription factor E2F1 and repressive
transcription factor Hes1 in prostate cancer progression.
Methods
Plasmids
The Hes1 expression plasmids (pcDNA-flag-WT-Hes1,
pcDNA-flag-DN-Hes1), which contain rat Hes1 gene and
the plasmid for E2F1, were described previously [10,18].
The construction of human δ-catenin-luciferase reporter
vectors (BK1 and BK5), based on pGL3-Basic reporter
vector (Promega), was previously reported [10]. pSV-b-
Galactosidase control vector (Promega) or pcDNA3
(Invitrogen) was used as a control vector.
In δ-catenin-luciferase reporter vector BK5 (containing
744 bp of δ-catenin promoter) [10], there are four E-
boxes (position in -425 to -437, -432 to -442, -493 to
-506, and -631 to -643), which are potential binding
sites for Hes1 (Figure 1A). These four E-boxes in δ-cate-
nin promoter were mutated via site-directed gene muta-
genesis one by one. The E-box in position -631 to -643
was mutated from ACGcgcgCGGCGA to ACGa-
tatCGGCGA using mutation primer set (5’- CAGGAGA
AGTGGAACGatatCGGCGAAGCGCCGCT-3’ and AGC
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obtained PCR product using wild BK5 vector as tem-
plate was digested with DpnI, cloned to DH5a bacteria,
and sequenced. The sequencing confirmed mutant BK5-
M1 was used as template to mutate the second E-box at
position -494 to -506, from CTGCcgcgCGCCG to
CTGCatatCGCCG, using primer set (5’-GGAGGCT-
GAGGCTGCatatCGCCGCGGGAGGAG-3’ and 5’-
CTCCTCCCGCGGCGatatGCAGCCTCAGCCTCC-3’).
The resulted mutant (BK5-M1, 2) vector mutated in the
above two E-boxes was then used as template to mutate
the third and fourth E-boxes at positions -425 to -437
and -432 to -442 using primer set (5’-AGGTGG
CGCGGGCCGCatatGGGGCGCAGCTCGGGA-3’ and
5’- TCCCGAGCTGCGCCCCatatGCGGCCCGCGC-
CACCT-3’) from GGGCCGCcgcgGGGGCGC to
GGGCCGCatatGGGGCGC. The final BK5-M1, 2, 3
mutant (BK5Mu) contains a 744 bp δ-catenin promoter
mutated in all known 4 E-boxes and was used to evalu-
ate the binding ability of Hes1 in δ-catenin promoter.
Antibodies
The antibodies used were as follows: mouse monoclonal
anti-δ-catenin Delta-30 (BD Bioscience), rabbit polyclo-
nal anti-δ-catenin antibody R1152 raised against 435-
530 amino acid and affinity purified essentially as
described [3], rabbit anti-Hes1 polyclonal antibody
(Millipore), mouse anti-flag antibody M5 (Kodak),
mouse monoclonal anti-actin (Calbiochem), and mouse
monoclonal anti-GAPDH mAb (6C5) (Calbiochem).
Mouse monoclonal anti-δ-catenin/NPRAP/Neurojungin
(J19) was a gift from Dr. Werner Franke.
Cell culture, transfection and siRNA against Hes1
CWR22-Rv1 and PC3 human prostate cancer cell lines,
as well as PZ-HPV-7 normal prostate cell lines were
from ATCC and maintained in RPMI 1640 media sup-
plemented with 10% FBS and 1% penicillin/streptomycin
(CWR22-Rv1 and PC3), or in Keratinocyte-SFM media
supplemented with EGF, bovine pituitary extract, and
1% penicillin/streptomycin (PZ-HPV-7) at 37°C in a 5%
CO2 atmosphere. Cells were transfected using Lipofecta-
mine Plus reagent (Invitrogen) or Fugene 6 reagent
(Roche) according to the manufacturer’s instructions.
For Hes1 knockdown experiments, specific siRNAs
directed against human Hes1 nucleotide sequences were
obtained from Darmacon Technologies (USA). The ON-
target plus smart siRNA oligonucleotide sequences were
as follows: ACGAGAGCAAGAAUAAAU, AGGCUGG
AGAGGCGGCUAA, UCAACACGACACCGGAUAA,
and ACUGCAUGACCCAGAUCAA. A scramble siRNA
was used as control.
g-Secretase inhibitor treatment and flow cytometry
Inhibition of endogenous Hes1 in PC3 and CWR22-
Rv1 cell lines was achieved by a 48-hour treatment of
20 μM DAPT (N- [N-(3, 5-difluorophenylacetyl- L
-alanyl)]-S-phenylglycine t-butyl ester) (Calbiochem), a
peptidomimetic inhibitor of g-secretase. Control plates
were treated using the solvent DMSO (dimethylsulfox-
ide) (Sigma) with the same final concentration. For cell
morphology and flow cytometry analyses, PC3 cells
were incubated with 20 μMD A P T ,3 0 0n MW P E - I I I -
31C (a transition-state analog of g-secretase) [34,35],
or DMSO (control), respectively for 48 hours. Cells in
multiple areas of culture plates were photographed for
morphological analyses before they were collected with
mild trypsinization and centrifugation. Cells were fixed
in ice-cold ethanol and stained with 50 μg/ml propi-
dium iodide containing RNase in the dark. The per-
centage of cells in each phase of the cell cycle (SubG1,
G1, S, and G2/M) was determined by flow cytometry
o naF A C S c a n( B DB i o s c i e n c e s ,P a l oA l t o ,C A )w i t h
ModFit 3.1 software (Varity Software House, Topsham,
ME). All data was presented as mean ± SEM and sta-
tistically evaluated with t-test. The confidence level
was set at 95%.
Luciferase reporter assay
Cell cultures in 12-well plates were transiently trans-
fected using Fugene 6 reagent with expression vectors
for several genes (E2F1, WT-Hes1 or DN-Hes1,l u c i f e r -
ase gene, GAL) as indicated in the result section. Luci-
ferase activity was measured 24 hours after transfection
using the Luciferase Assay system (Promega) and nor-
malized to b-galactosidase activity, which was used as
control to determine transfection efficiency. All experi-
ments were performed in quintuplicates. Whenever
errors were displayed they represented standard devia-
tion of mean (SDM) except in cell cycle measurements
where SEM was employed.
Electrophoretic mobility shift analysis (EMSA)
Nuclear extracts were prepared from PC3 or CWR22-
Rv1 cells transfected with pcDNA-flag-WT-Hes1 using
Fugene 6 reagent (Roche) 24 h before preparation
according to instructions for NE-PER Nuclear and Cyto-
plasmic Extraction Reagents (Pierce Biotechnology,
Rockford, IL). Oligonucleotides containing the HLH
motif derived in δ-catenin promoter (5’-GGGCGA
AGGCCCAGAGGCCTTCCTTGGCACATGTTTTG
GGTTTCGTTTTTCAACAAGACT-3’) [the E-box/HLH
motif is underlined] (marked as ** in Figure 1A) and its
reverse complement sequences were 3’-end labeled sepa-
rately with Biotin 3’ End DNA Labeling Kit (Pierce
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beled shorter oligonucleotides (CCTTCCTTGGCA-
CATG TTTTGGGTT) [the E-box/HLH motif is
underlined] and its reverse complement sequences were
annealed and used as competitors. Mutant probe was
produced when E-box sequence CACATG was mutated
to GTCTCA. EMSA reactions were performed accord-
ing to instructions of LightShift Chemiluminescent
EMSA Kit (Pierce Biotechnology, Rockford, IL).
Nuclear protein extracts (2 μl) were incubated for 20
m i na tr o o mt e m p e r a t u r ew i t h1μlo fn o n - s p e c i f i c
competitor DNA Poly (dI·dC) and 20 fmol of biotin-
labeled oligonucleotides. Competition assays were per-
formed by mixing non-specific competitor DNA with 4
pmol unlabeled oligonucleotides (200-fold molar
excess) and nuclear extracts before addition of probes.
Hes-1 antibody (2 μl; Santa Cruz, CA) was used for
disrupt-shift experiments. Normal goat IgG, Pax-6
antibody (2ul; Santa Cruz, CA), and δ-catenin antibody
(2 μl; Transduction Laboratory, BD Biosciences) were
used as a non-specific antibody. Antibodies were
mixed with nuclear protein on ice for 20 min before
the addition of probe DNA. Protein-DNA complexes
were run on a 6% acrylamide gel, electrophoretically
transferred to nylon membrane and visualized by Che-
miluminescent Nucleic Acid Detection Module (Pierce
Biotechnology, Rockford, IL).
Chromatin immunoprecipitation (ChIP)
PC3 cells were collected and ChIP assay was performed
to test Hes1 protein regulation on δ-catenin promoter
using the Abcam ChIP kit (Abcam, Cambridge, MA)
according to the manufacturer’si n s t r u c t i o n .C r o s s - l i n k -
i n gw a sp e r f o r m e db ya d d i n gf o r m a l d e h y d et oaf i n a l
concentration of 1% at room temperature for 10 minutes
and reaction stopped by the addition of 125 mM glycine.
Cells were washed with ice-cold phosphate buffered sal-
ine containing 0.1 mM PMSF. Cell pellets, collected by
centrifugation at 2000 rpm at 4°C, were resuspended in 1
ml of ChIP sonication buffer. DNA was sheared by soni-
cation and the cell debris was pelleted by centrifugation
at 14,000 g for 15 minutes. The pre-cleared whole cell
extract was incubated with or without the antibodies, as
described in the legend, at 4°C overnight. Immunopreci-
pitated, immune complexes were collected using anti-
Hes 1 conjugated-Protein A. Anti-Histone 3 (ab1791)
antibody and IgG were used as positive control and nega-
tive control, respectively. The primer sets of real-time
PCR for δ-catenin promoter were as follows: Forward: 5’-
CCTTCCAGCTTT CGCCTA G-3’, Reverse: 5’-TCC
ACTTCTCCTG GTTTTCG-3’;G A P D Hw a su s e da s
control, the primers were as follows: Forward: 5’-AGA
AACAGGAGGTCCC TACTCCC-3’,R e v e r s e :5 ’-AGAG
CGCGAAAGGAAA GA AAG CGT -3’.
Mouse tissue preparation
The development of mouse neuroendocrine tumors
(NE-10) was described before [14]. Male CD1 mice
(Charles River Lab, Wilmington, MA) were obtained
and used at 10 weeks of age. Mice were kept under
pathogen free conditions and sacrificed by cervical dislo-
cation according to the guidelines of East Carolina Uni-
versity Animal Use Protocol. The prostates were
dissected into three different lobes (ventral, lateral-dor-
sal, and anterior lobe) under a dissecting microscope.
Immunohistochemistry
For NE-10 and CD-1 mice prostate tissue immunohisto-
chemistry, 5 μm tissue sections of formalin-fixed, paraf-
fin-embedded blocks were deparaffinized and
rehydrated; endogenous peroxidase was blocked by incu-
bation with hydrogen peroxide. The sections were
immunostained using rabbit anti-δ-catenin R1152
(1:100) (Abcam, Cambridge, MA) followed by streptavi-
din-biotin peroxidase method for detection. The immu-
nostaining was done in Dako Autostainer (Carpinteria,
CA) according to the manufacture instruction.
RT-PCR and real-time qRT-PCR
Total RNAs were extracted from cultured cells or
mouse tissues using an RNeasy mini kit (Qiagen) with
residual genomic DNA removed by RNase-free DNase
(Qiagen) treatment. 1~2 μg of total RNA was reverse-
transcribed using Retroscript reverse transcription kit
(Applied Biosystems).
For RT-PCR, the reaction was initiated using Advan-
tage 2 polymerase or Advantage-GC 2 polymerase
(Clontech). The following forward and reverse primers
were used to produce gene specific fragments: human δ-
catenin,f o r w a r d5 ’-ATGTTTGCGAGGAAGCCGC-3’
and reverse 5’-GTCTGGTTGCTATGGTAGCTGGC-3’;
mouse δ-catenin,f o r w a r d5 ’-GAGCTATGCCTGTCC-
CAGAC-3’ and reverse 5’-AGCTGAGAAGGGG
CTGTGT-3’; human Hes1,f o r w a r d5 ’-CAGCGAGTGC
ATGAACGAGGTGA-3’ and reverse 5’-A G G T G C C
GCTGTTGCTGGTGTAGA-3’; mouse Hes1,f o r w a r d5 ’-
AAGAGGCGAAGGGCAAGAATAAAT-3’ and reverse
5’-CCGGGGATGGGCACAAG-3’;r a tHes1,5 ’-ACA
GCCTCTGAGCACAGAAAGTCA-3’ and reverse 5’-TG
AGGAAAGCAAATTGGCCGTCAG-3’; human Hey1,
forward 5’- TCGAGTTCGACTGGTTTCGCATCT-3’
and reverse 5’- AGGTCTATAGGGCTTGCCAAGGTT-
3’;h u m a nE2F1,f o r w a r d5 ’-ACTCCTCGCAGATCGT-
CATCATCT-3’ and reverse 5’-GGACGTTGGTGA
TGTCATAGATGCG-3’;m o u s eE 2 F 1 ,f o r w a r d5 ’-GC
ATCCAGCTCATTGCCAAGAAGT-3’ and reverse 5’-
TGGTGACAGTTGGTCCTCTTCCAT-3’;h u m a nLEF-
1,f o r w a r d5 ’-CCCGCTTCCGCCCGCTGTCC-3’ and
reverse 5’-CGGGGTGTTCTCTGGCCTTGTCGT-3’;
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GAGAA-3’ and reverse 5’-CCCCGGGACAAAGCAAA
TGGAAGT-3’; human CDK8,f o r w a r d5 ’-AGAA
GCTGCTTACCATGGACCCAA-3’ and reverse 5’-T G
GTGGAACTTGGCTACTGGACAT-3’; human andro-
gen receptor (AR),5 ’-AGACGCTTCTACCAGCTCAC
CAA-3’ and 5’- AGCTCTCTAAACTTCCCGTGGCAT-
3’; human c-Myc, forward TCCACACATCAGCA
CAACTACGCA and reverse TCAGCCAAGGTTGT
GAGGTTGCAT; human GAPDH (as control), forward
5’-GGGGAGCCAAAAGGGTCATCATCT-3’ and
reverse 5’- GACGCCTGCTTCACCACCTTCTTG-3’;
mouse GAPDH (as control), forward 5’-AACTTTGG
CATTGTGGAAGG-3’ and reverse 5’- TGTGAGGGA
GATGCTCAGTG-3’. PCR products were analyzed by
electrophoresis in 1.0% agarose gel containing ethidium
bromide and photographed under UV illumination.
For real time qPCR, reaction was initiated using IQ
SYBR green supermix (Bio-Rad) in an iCycler iQ Multi-
color Detection System (Bio-Rad). The relative mRNA
levels of tested genes were calculated against control
GAPDH. The following primers for real time qPCR were
used: mouse δ-catenin, forward 5’- ACCTCGGGAAAT-
GATCAGCCTCAA-3’ and reverse 5’-T A G T T C C
GTGGTAAGTGGCGTTGT-3’; mouse Hes1, forward 5’-
CAACACGACACCGGACAAACCAAA-3’ and reverse
5’- TGGAATGCCGGGAGCTATCTTTCT-3’;m o u s e
E2F1,f o r w a r d5 ’-TCATGCCAGGAGACATCC-3’ and
reverse 5’-CAATACTGCTTCTTGCTCCA-3’;m o u s ec-
Myc,f o r w a r d5 ’- TGCTGCATGAGGAGACA -3’ and
reverse 5’-TCGGGATGGAGATGAGC-3’;m o u s eAR,
forward 5’- CTGCCTGATCTGTGGAGA-3’ and reverse
5’- CAATGGTACAATCGTTTCTGC-3’;m o u s eCDK8,
forward 5’- ACATTCTGGTACCGAGCT-3’ and reverse
5’- CACCCTATAGCCCAAATATCAA-3’;a n dm o u s e
GAPDH (as control), forward 5’-TCAACAGCAACTCC-
CACTCTTCCA-3’ and reverse 5’- ACCCTGTT
GCTGTAGCCGTATTCA-3’. The real-time PCR primer
set for human genes were: human δ-catenin,f o r w a r d5 ’-
GCCTCAGTCAAAGAACAGGA-3’and reverse 5’-AG
CTTGCATCGCTCCA-3’;h u m a nHes1,f o r w a r d5 ’-CT
GAAGAAAGATAGCTCGCG-3’ and reverse 5’-ACTT
CCCCAGCACACTT-3’; human E2F1,f o r w a r d5 ’-C T C
CGAGGACACTGACA-3’ and reverse 5’-C A C C A T A A
CCATCTGCTCTG-3’;h u m a nGAPDH,f o r w a r d5 ’-AC
AGTCAGCCGCATCTT-3’ and 5’-GCCCAATACGAC
CAAATCC-3’.
Immunofluorescence light microscopy
Cells on coverslips were fixed in 4% paraformaldehyde/
phosphate buffered saline, permeabilized with 0.2% Tri-
ton X-100, blocked with 10% BSA in PBS, double immu-
nostained with mouse anti-flag antibody M5 (1:600)/
secondary antibody mouse Cy3 (1:400) and then rabbit
polyclonal anti-δ-catenin antibody R1152 (1:50)/second-
ary antibody rabbit FITC (1:100). The nuclei were coun-
ter stained with Hoechst 33258 (2 μg/ml). The slides
were mounted using Molecular Probe’s Antifade medium
and were analyzed under Zeiss Axiovert inverted fluores-
cent light microscope (Carl Zeiss) equipped with Meta-
Morph software (Molecular Devices).
Western blot
Cultured cells were lysed in 10 mM HEPES, pH 7.3, 150
mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.5% deoxy-
cholate, 0.2% SDS with protease inhibitor cocktails. Equal
amounts of protein samples were analyzed directly by
SDS-PAGE. After proteins were transferred to nitrocellu-
lose membranes (PGC Scientifics), Western blots were
performed with appropriate antibodies and developed with
ECL Western blotting detection reagents (Amersham).
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